You are currently viewing a new version of our website. To view the old version click .
Proceedings
  • Abstract
  • Open Access

12 April 2024

From Function to Drug Discovery: Insights into Hypothetical Protein Rv1979c from Mycobacterium tuberculosis †

and
SRM DBT Platform, SRM Institute of Science and Technology, Chengalpattu 603203, India
*
Author to whom correspondence should be addressed.
Presented at the 3rd International Electronic Conference on Biomolecules, 23–25 April 2024; Available online: https://sciforum.net/event/IECBM2024.
This article belongs to the Proceedings The 3rd International Electronic Conference on Biomolecules
Mycobacterium tuberculosis is the causative agent of tuberculosis (TB), a highly contagious disease affecting millions of individuals globally. The emergence of drug resistance becomes a significant obstacle in the treatment of tuberculosis (TB). The Mycobacterium tuberculosis protein Rv1979c has been implicated in drug resistance, yet its function and potential inhibitors remain largely unexplored. In this study, we employed a comprehensive computational approach to unravel the role of Rv1979c and identify potential inhibitors from natural sources.
This investigation was initiated by revealing the three-dimensional structure of Rv1979c via the threading/fold recognition method. Subsequently, a functional analysis of its molecular mechanism using a variety of computational tools yielded valuable insights. In addition, we screened a diverse collection of 11,708 phytochemicals against the Rv1979c target to identify potential inhibitors followed by molecular dynamic simulation. This exhaustive screening and simulation led to the identification of several prospective phytochemical candidates with significant binding affinity to the protein, indicating their potential as Rv1979c inhibitors.
This interdisciplinary study combines computational biology and drug discovery techniques to cast light on the function of Rv1979c and reveal potential strategies for combating pathogenesis in M. tuberculosis. The findings provide a foundation for further experimental validation and the development of novel therapeutic agents to address the evolving challenges of TB drug resistance.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/proceedings2024103069/s1, Conference poster.

Author Contributions

Conceptualization, M.A.S. and T.T.; methodology, M.A.S.; software M.A.S.; investigation, M.A.S.; resources, M.A.S.; data curation, M.A.S.; writing—original draft preparation, M.A.S.; writing—review and editing, M.A.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

The phytochemical data used to perform virtual screening was obtained from IMPPAT (https://cb.imsc.res.in/imppat/).

Conflicts of Interest

The authors declare no conflict of interest.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.